sepantronium bromide  (TargetMol)

Journal: Blood Neoplasia

Article Title: BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

doi: 10.1016/j.bneo.2024.100040

Figure Lengend Snippet: BIRC5 as a precision medicine target for DNMT3A-mutant T-ALL. (A) Cell viability of indicated T-ALL specimens (normalized to negative control small interfering [siRNA]) 48 hours after nucleofection with BIRC5 siRNA. (B) Compiled normalized cell viability averaged for individual WT DNMT3A and DNMT3A -mutant T-ALL samples after nucleofection with BIRC5 siRNA. (C) Cell viability of indicated T-ALL specimens (normalized to DMSO control) after 48 hours exposure to YM155. (D) Compiled normalized cell viability averaged for individual WT DNMT3A and DNMT3A -mutant T-ALL samples after 48 hours exposure to YM155. (E) Kaplan-Meier plots of NSG mice xenografted with indicated T-ALL specimens after CRISPR/Cas9 genome targeting with indicated gRNAs. (F) VAF of CRISPR edits from indicated gRNAs in T-ALL blasts from peripheral blood (6-8 weeks after transplant) and BM of moribund mice (euthanized) normalized to initial targeting efficiency 48 hours after nucleofection (initial) at time of transplant.

Article Snippet: For YM155 (Sepantronium Bromide) treatment, 2 × 10 6 primary human T-ALL cells were seeded in 6-well tissue culture plate wells and incubated with YM155 (Selleckchem, no. S1130) at a concentration of 1 μM for 48 hours, then assayed for viability as described above.

Techniques: Clinical Proteomics, Mutagenesis, Negative Control, Control, CRISPR